nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetazolamide—AQP1—saliva-secreting gland—thyroid cancer	0.0289	0.0934	CbGeAlD
Acetazolamide—CA6—saliva-secreting gland—thyroid cancer	0.0224	0.0723	CbGeAlD
Acetazolamide—AQP1—trachea—thyroid cancer	0.0223	0.0721	CbGeAlD
Acetazolamide—AQP1—Vasopressin regulates renal water homeostasis via Aquaporins—PRKAR1A—thyroid cancer	0.0221	0.0831	CbGpPWpGaD
Acetazolamide—AQP1—Aquaporin-mediated transport—PRKAR1A—thyroid cancer	0.0192	0.0725	CbGpPWpGaD
Acetazolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EPO—thyroid cancer	0.0187	0.0702	CbGpPWpGaD
Acetazolamide—CA7—trachea—thyroid cancer	0.0178	0.0576	CbGeAlD
Acetazolamide—AQP1—thyroid gland—thyroid cancer	0.0177	0.057	CbGeAlD
Acetazolamide—AQP1—head—thyroid cancer	0.0157	0.0506	CbGeAlD
Acetazolamide—CA3—thyroid gland—thyroid cancer	0.013	0.0418	CbGeAlD
Acetazolamide—CA6—head—thyroid cancer	0.0121	0.0392	CbGeAlD
Acetazolamide—CA4—neck—thyroid cancer	0.0119	0.0385	CbGeAlD
Acetazolamide—CA12—trachea—thyroid cancer	0.0116	0.0374	CbGeAlD
Acetazolamide—CA3—head—thyroid cancer	0.0115	0.0371	CbGeAlD
Acetazolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—thyroid cancer	0.0111	0.0418	CbGpPWpGaD
Acetazolamide—AQP1—lymph node—thyroid cancer	0.011	0.0354	CbGeAlD
Acetazolamide—Hypoglycaemia—Vandetanib—thyroid cancer	0.0106	0.025	CcSEcCtD
Acetazolamide—Hyponatraemia—Vandetanib—thyroid cancer	0.0104	0.0245	CcSEcCtD
Acetazolamide—AQP1—Spinal Cord Injury—LGALS3—thyroid cancer	0.00992	0.0373	CbGpPWpGaD
Acetazolamide—CA2—neck—thyroid cancer	0.00989	0.0319	CbGeAlD
Acetazolamide—Hypokalaemia—Vandetanib—thyroid cancer	0.00945	0.0222	CcSEcCtD
Acetazolamide—CA4—saliva-secreting gland—thyroid cancer	0.00931	0.03	CbGeAlD
Acetazolamide—CA9—Cellular response to hypoxia—EPO—thyroid cancer	0.00824	0.031	CbGpPWpGaD
Acetazolamide—CA5B—thyroid gland—thyroid cancer	0.00823	0.0266	CbGeAlD
Acetazolamide—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00819	0.0193	CcSEcCtD
Acetazolamide—CA12—head—thyroid cancer	0.00814	0.0263	CbGeAlD
Acetazolamide—CA3—lymph node—thyroid cancer	0.00805	0.026	CbGeAlD
Acetazolamide—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00801	0.0189	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00793	0.0187	CcSEcCtD
Acetazolamide—Hepatic failure—Sorafenib—thyroid cancer	0.00779	0.0183	CcSEcCtD
Acetazolamide—CA2—saliva-secreting gland—thyroid cancer	0.00772	0.0249	CbGeAlD
Acetazolamide—Haematuria—Vandetanib—thyroid cancer	0.00763	0.018	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00756	0.0178	CcSEcCtD
Acetazolamide—CA5B—head—thyroid cancer	0.0073	0.0236	CbGeAlD
Acetazolamide—CA4—trachea—thyroid cancer	0.00718	0.0232	CbGeAlD
Acetazolamide—Hyponatraemia—Sorafenib—thyroid cancer	0.00703	0.0166	CcSEcCtD
Acetazolamide—Erythema multiforme—Vandetanib—thyroid cancer	0.00679	0.016	CcSEcCtD
Acetazolamide—AQP1—Spinal Cord Injury—CDK1—thyroid cancer	0.00677	0.0255	CbGpPWpGaD
Acetazolamide—CA1—head—thyroid cancer	0.00645	0.0208	CbGeAlD
Acetazolamide—Hypokalaemia—Sorafenib—thyroid cancer	0.00637	0.015	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.0063	0.0148	CcSEcCtD
Acetazolamide—Dysgeusia—Vandetanib—thyroid cancer	0.00612	0.0144	CcSEcCtD
Acetazolamide—CA2—trachea—thyroid cancer	0.00595	0.0192	CbGeAlD
Acetazolamide—CA4—thyroid gland—thyroid cancer	0.00568	0.0183	CbGeAlD
Acetazolamide—Convulsion—Vandetanib—thyroid cancer	0.00542	0.0128	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00535	0.0126	CcSEcCtD
Acetazolamide—CA5B—lymph node—thyroid cancer	0.00511	0.0165	CbGeAlD
Acetazolamide—Hepatobiliary disease—Sorafenib—thyroid cancer	0.0051	0.012	CcSEcCtD
Acetazolamide—CA4—head—thyroid cancer	0.00504	0.0163	CbGeAlD
Acetazolamide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00499	0.0118	CcSEcCtD
Acetazolamide—CA9—Cellular response to hypoxia—HIF1A—thyroid cancer	0.0049	0.0185	CbGpPWpGaD
Acetazolamide—CA9—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.00483	0.0182	CbGpPWpGaD
Acetazolamide—CA2—thyroid gland—thyroid cancer	0.00471	0.0152	CbGeAlD
Acetazolamide—Paraesthesia—Vandetanib—thyroid cancer	0.00458	0.0108	CcSEcCtD
Acetazolamide—Erythema multiforme—Sorafenib—thyroid cancer	0.00458	0.0108	CcSEcCtD
Acetazolamide—Tinnitus—Sorafenib—thyroid cancer	0.00452	0.0106	CcSEcCtD
Acetazolamide—CA1—lymph node—thyroid cancer	0.00451	0.0146	CbGeAlD
Acetazolamide—Flushing—Sorafenib—thyroid cancer	0.0045	0.0106	CcSEcCtD
Acetazolamide—Dyspepsia—Vandetanib—thyroid cancer	0.00449	0.0106	CcSEcCtD
Acetazolamide—Decreased appetite—Vandetanib—thyroid cancer	0.00443	0.0104	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0044	0.0104	CcSEcCtD
Acetazolamide—Glycosuria—Epirubicin—thyroid cancer	0.0044	0.0104	CcSEcCtD
Acetazolamide—Fatigue—Vandetanib—thyroid cancer	0.0044	0.0104	CcSEcCtD
Acetazolamide—Injection site pain—Epirubicin—thyroid cancer	0.00437	0.0103	CcSEcCtD
Acetazolamide—Blood disorder—Epirubicin—thyroid cancer	0.00427	0.0101	CcSEcCtD
Acetazolamide—CA2—head—thyroid cancer	0.00418	0.0135	CbGeAlD
Acetazolamide—Dysgeusia—Sorafenib—thyroid cancer	0.00413	0.00972	CcSEcCtD
Acetazolamide—Glycosuria—Doxorubicin—thyroid cancer	0.00407	0.00959	CcSEcCtD
Acetazolamide—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00406	0.00955	CcSEcCtD
Acetazolamide—Injection site pain—Doxorubicin—thyroid cancer	0.00404	0.00951	CcSEcCtD
Acetazolamide—Body temperature increased—Vandetanib—thyroid cancer	0.00403	0.0095	CcSEcCtD
Acetazolamide—Blood disorder—Doxorubicin—thyroid cancer	0.00395	0.0093	CcSEcCtD
Acetazolamide—CA9—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.00379	0.0143	CbGpPWpGaD
Acetazolamide—Leukopenia—Sorafenib—thyroid cancer	0.00377	0.00889	CcSEcCtD
Acetazolamide—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00375	0.00884	CcSEcCtD
Acetazolamide—Asthenia—Vandetanib—thyroid cancer	0.00366	0.00862	CcSEcCtD
Acetazolamide—CA4—lymph node—thyroid cancer	0.00353	0.0114	CbGeAlD
Acetazolamide—Diarrhoea—Vandetanib—thyroid cancer	0.00349	0.00822	CcSEcCtD
Acetazolamide—Melaena—Epirubicin—thyroid cancer	0.00348	0.0082	CcSEcCtD
Acetazolamide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00344	0.0081	CcSEcCtD
Acetazolamide—AQP1—Metabolism—MINPP1—thyroid cancer	0.00342	0.0129	CbGpPWpGaD
Acetazolamide—Shock—Sorafenib—thyroid cancer	0.00339	0.00797	CcSEcCtD
Acetazolamide—Dizziness—Vandetanib—thyroid cancer	0.00337	0.00795	CcSEcCtD
Acetazolamide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00337	0.00794	CcSEcCtD
Acetazolamide—Aplastic anaemia—Epirubicin—thyroid cancer	0.00335	0.00788	CcSEcCtD
Acetazolamide—Vomiting—Vandetanib—thyroid cancer	0.00324	0.00764	CcSEcCtD
Acetazolamide—Melaena—Doxorubicin—thyroid cancer	0.00322	0.00759	CcSEcCtD
Acetazolamide—Headache—Vandetanib—thyroid cancer	0.0032	0.00753	CcSEcCtD
Acetazolamide—AQP1—Spinal Cord Injury—PTGS2—thyroid cancer	0.00312	0.0118	CbGpPWpGaD
Acetazolamide—Aplastic anaemia—Doxorubicin—thyroid cancer	0.0031	0.00729	CcSEcCtD
Acetazolamide—Nausea—Vandetanib—thyroid cancer	0.00303	0.00714	CcSEcCtD
Acetazolamide—Dyspepsia—Sorafenib—thyroid cancer	0.00303	0.00713	CcSEcCtD
Acetazolamide—Decreased appetite—Sorafenib—thyroid cancer	0.00299	0.00705	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00297	0.007	CcSEcCtD
Acetazolamide—Fatigue—Sorafenib—thyroid cancer	0.00297	0.00699	CcSEcCtD
Acetazolamide—CA3—Metabolism—MINPP1—thyroid cancer	0.00296	0.0112	CbGpPWpGaD
Acetazolamide—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00296	0.00697	CcSEcCtD
Acetazolamide—Photosensitivity—Epirubicin—thyroid cancer	0.00295	0.00694	CcSEcCtD
Acetazolamide—CA2—lymph node—thyroid cancer	0.00293	0.00944	CbGeAlD
Acetazolamide—AQP1—Metabolism—NDUFA13—thyroid cancer	0.00291	0.0109	CbGpPWpGaD
Acetazolamide—Hepatic failure—Epirubicin—thyroid cancer	0.00288	0.00678	CcSEcCtD
Acetazolamide—AQP1—Spinal Cord Injury—CCND1—thyroid cancer	0.00282	0.0106	CbGpPWpGaD
Acetazolamide—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00274	0.00645	CcSEcCtD
Acetazolamide—Urticaria—Sorafenib—thyroid cancer	0.00273	0.00644	CcSEcCtD
Acetazolamide—AQP1—Metabolism—CHST14—thyroid cancer	0.00273	0.0103	CbGpPWpGaD
Acetazolamide—Photosensitivity—Doxorubicin—thyroid cancer	0.00273	0.00642	CcSEcCtD
Acetazolamide—Body temperature increased—Sorafenib—thyroid cancer	0.00272	0.00641	CcSEcCtD
Acetazolamide—AQP1—Transmembrane transport of small molecules—CP—thyroid cancer	0.0027	0.0102	CbGpPWpGaD
Acetazolamide—AQP1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.0027	0.0102	CbGpPWpGaD
Acetazolamide—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00267	0.0063	CcSEcCtD
Acetazolamide—Hepatic failure—Doxorubicin—thyroid cancer	0.00266	0.00627	CcSEcCtD
Acetazolamide—AQP1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00266	0.01	CbGpPWpGaD
Acetazolamide—Hypoglycaemia—Epirubicin—thyroid cancer	0.00265	0.00624	CcSEcCtD
Acetazolamide—Hyponatraemia—Epirubicin—thyroid cancer	0.0026	0.00612	CcSEcCtD
Acetazolamide—CA3—Metabolism—NDUFA13—thyroid cancer	0.00252	0.00949	CbGpPWpGaD
Acetazolamide—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00247	0.00583	CcSEcCtD
Acetazolamide—Asthenia—Sorafenib—thyroid cancer	0.00247	0.00581	CcSEcCtD
Acetazolamide—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00245	0.00578	CcSEcCtD
Acetazolamide—Ataxia—Epirubicin—thyroid cancer	0.00243	0.00573	CcSEcCtD
Acetazolamide—Hyponatraemia—Doxorubicin—thyroid cancer	0.0024	0.00566	CcSEcCtD
Acetazolamide—CA3—Metabolism—CHST14—thyroid cancer	0.00237	0.00892	CbGpPWpGaD
Acetazolamide—CA9—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.00236	0.00888	CbGpPWpGaD
Acetazolamide—Hypokalaemia—Epirubicin—thyroid cancer	0.00235	0.00555	CcSEcCtD
Acetazolamide—Diarrhoea—Sorafenib—thyroid cancer	0.00235	0.00555	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00233	0.00549	CcSEcCtD
Acetazolamide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00231	0.00871	CbGpPWpGaD
Acetazolamide—Dizziness—Sorafenib—thyroid cancer	0.00228	0.00536	CcSEcCtD
Acetazolamide—CA9—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.00226	0.00849	CbGpPWpGaD
Acetazolamide—Ataxia—Doxorubicin—thyroid cancer	0.00225	0.0053	CcSEcCtD
Acetazolamide—AQP1—Metabolism—HPGD—thyroid cancer	0.0022	0.00829	CbGpPWpGaD
Acetazolamide—Vomiting—Sorafenib—thyroid cancer	0.00219	0.00515	CcSEcCtD
Acetazolamide—Hypokalaemia—Doxorubicin—thyroid cancer	0.00218	0.00513	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00216	0.00508	CcSEcCtD
Acetazolamide—Headache—Sorafenib—thyroid cancer	0.00216	0.00508	CcSEcCtD
Acetazolamide—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00213	0.00802	CbGpPWpGaD
Acetazolamide—Nausea—Sorafenib—thyroid cancer	0.00204	0.00481	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00204	0.00481	CcSEcCtD
Acetazolamide—AQP1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00202	0.00761	CbGpPWpGaD
Acetazolamide—Drowsiness—Epirubicin—thyroid cancer	0.00199	0.0047	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00198	0.00466	CcSEcCtD
Acetazolamide—CA14—Metabolism—MINPP1—thyroid cancer	0.00191	0.00719	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—HPGD—thyroid cancer	0.00191	0.00719	CbGpPWpGaD
Acetazolamide—Haematuria—Epirubicin—thyroid cancer	0.0019	0.00448	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00189	0.00445	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00189	0.00444	CcSEcCtD
Acetazolamide—Agranulocytosis—Epirubicin—thyroid cancer	0.00186	0.00438	CcSEcCtD
Acetazolamide—CA5A—Metabolism—MINPP1—thyroid cancer	0.00186	0.00701	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—MINPP1—thyroid cancer	0.00186	0.00701	CbGpPWpGaD
Acetazolamide—AQP1—Spinal Cord Injury—TP53—thyroid cancer	0.00186	0.007	CbGpPWpGaD
Acetazolamide—Drowsiness—Doxorubicin—thyroid cancer	0.00184	0.00435	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00183	0.00431	CcSEcCtD
Acetazolamide—Hypoaesthesia—Epirubicin—thyroid cancer	0.00178	0.00419	CcSEcCtD
Acetazolamide—Haematuria—Doxorubicin—thyroid cancer	0.00176	0.00414	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00174	0.00411	CcSEcCtD
Acetazolamide—CA5B—Metabolism—MINPP1—thyroid cancer	0.00174	0.00654	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—MINPP1—thyroid cancer	0.00174	0.00654	CbGpPWpGaD
Acetazolamide—Agranulocytosis—Doxorubicin—thyroid cancer	0.00172	0.00406	CcSEcCtD
Acetazolamide—AQP1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.0017	0.0064	CbGpPWpGaD
Acetazolamide—Erythema multiforme—Epirubicin—thyroid cancer	0.00169	0.00399	CcSEcCtD
Acetazolamide—Tinnitus—Epirubicin—thyroid cancer	0.00167	0.00393	CcSEcCtD
Acetazolamide—Flushing—Epirubicin—thyroid cancer	0.00166	0.00391	CcSEcCtD
Acetazolamide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00165	0.00388	CcSEcCtD
Acetazolamide—CA14—Metabolism—NDUFA13—thyroid cancer	0.00162	0.00611	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—MINPP1—thyroid cancer	0.00161	0.00606	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—NDUFA13—thyroid cancer	0.00158	0.00596	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—NDUFA13—thyroid cancer	0.00158	0.00596	CbGpPWpGaD
Acetazolamide—Erythema multiforme—Doxorubicin—thyroid cancer	0.00157	0.00369	CcSEcCtD
Acetazolamide—Tinnitus—Doxorubicin—thyroid cancer	0.00154	0.00364	CcSEcCtD
Acetazolamide—Flushing—Doxorubicin—thyroid cancer	0.00154	0.00362	CcSEcCtD
Acetazolamide—CA14—Metabolism—CHST14—thyroid cancer	0.00153	0.00575	CbGpPWpGaD
Acetazolamide—Dysgeusia—Epirubicin—thyroid cancer	0.00153	0.00359	CcSEcCtD
Acetazolamide—CA5A—Metabolism—CHST14—thyroid cancer	0.00149	0.0056	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—CHST14—thyroid cancer	0.00149	0.0056	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—NDUFA13—thyroid cancer	0.00148	0.00556	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—NDUFA13—thyroid cancer	0.00148	0.00556	CbGpPWpGaD
Acetazolamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.00145	0.00341	CcSEcCtD
Acetazolamide—Agitation—Epirubicin—thyroid cancer	0.00143	0.00337	CcSEcCtD
Acetazolamide—CA1—C-MYB transcription factor network—PTGS2—thyroid cancer	0.00141	0.00533	CbGpPWpGaD
Acetazolamide—Dysgeusia—Doxorubicin—thyroid cancer	0.00141	0.00333	CcSEcCtD
Acetazolamide—Malaise—Epirubicin—thyroid cancer	0.00141	0.00331	CcSEcCtD
Acetazolamide—Leukopenia—Epirubicin—thyroid cancer	0.00139	0.00329	CcSEcCtD
Acetazolamide—CA5B—Metabolism—CHST14—thyroid cancer	0.00139	0.00523	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—CHST14—thyroid cancer	0.00139	0.00523	CbGpPWpGaD
Acetazolamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00138	0.00521	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—NDUFA13—thyroid cancer	0.00137	0.00515	CbGpPWpGaD
Acetazolamide—Convulsion—Epirubicin—thyroid cancer	0.00135	0.00318	CcSEcCtD
Acetazolamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00134	0.00315	CcSEcCtD
Acetazolamide—Agitation—Doxorubicin—thyroid cancer	0.00132	0.00312	CcSEcCtD
Acetazolamide—Discomfort—Epirubicin—thyroid cancer	0.00131	0.00309	CcSEcCtD
Acetazolamide—Malaise—Doxorubicin—thyroid cancer	0.0013	0.00306	CcSEcCtD
Acetazolamide—Leukopenia—Doxorubicin—thyroid cancer	0.00129	0.00304	CcSEcCtD
Acetazolamide—CA12—Metabolism—CHST14—thyroid cancer	0.00129	0.00484	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—MINPP1—thyroid cancer	0.00128	0.00483	CbGpPWpGaD
Acetazolamide—Confusional state—Epirubicin—thyroid cancer	0.00128	0.00302	CcSEcCtD
Acetazolamide—CA1—C-MYB transcription factor network—CCND1—thyroid cancer	0.00128	0.00481	CbGpPWpGaD
Acetazolamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.00127	0.003	CcSEcCtD
Acetazolamide—AQP1—Metabolism—TPR—thyroid cancer	0.00126	0.00476	CbGpPWpGaD
Acetazolamide—Shock—Epirubicin—thyroid cancer	0.00125	0.00295	CcSEcCtD
Acetazolamide—CA9—Cellular responses to stress—EPO—thyroid cancer	0.00125	0.00471	CbGpPWpGaD
Acetazolamide—Convulsion—Doxorubicin—thyroid cancer	0.00125	0.00294	CcSEcCtD
Acetazolamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.00125	0.00293	CcSEcCtD
Acetazolamide—AQP1—Metabolism—PRKAR1A—thyroid cancer	0.00124	0.00469	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—MINPP1—thyroid cancer	0.00123	0.00463	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—HPGD—thyroid cancer	0.00123	0.00463	CbGpPWpGaD
Acetazolamide—Discomfort—Doxorubicin—thyroid cancer	0.00121	0.00286	CcSEcCtD
Acetazolamide—CA5A—Metabolism—HPGD—thyroid cancer	0.0012	0.00451	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—HPGD—thyroid cancer	0.0012	0.00451	CbGpPWpGaD
Acetazolamide—Confusional state—Doxorubicin—thyroid cancer	0.00119	0.00279	CcSEcCtD
Acetazolamide—CA1—Metabolism—MINPP1—thyroid cancer	0.00118	0.00444	CbGpPWpGaD
Acetazolamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00118	0.00277	CcSEcCtD
Acetazolamide—Shock—Doxorubicin—thyroid cancer	0.00116	0.00273	CcSEcCtD
Acetazolamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00115	0.00271	CcSEcCtD
Acetazolamide—Paraesthesia—Epirubicin—thyroid cancer	0.00114	0.00269	CcSEcCtD
Acetazolamide—Somnolence—Epirubicin—thyroid cancer	0.00113	0.00266	CcSEcCtD
Acetazolamide—Dyspepsia—Epirubicin—thyroid cancer	0.00112	0.00264	CcSEcCtD
Acetazolamide—CA7—Metabolism—HPGD—thyroid cancer	0.00112	0.00422	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—HPGD—thyroid cancer	0.00112	0.00422	CbGpPWpGaD
Acetazolamide—Decreased appetite—Epirubicin—thyroid cancer	0.00111	0.0026	CcSEcCtD
Acetazolamide—CA1—C-MYB transcription factor network—NRAS—thyroid cancer	0.0011	0.00415	CbGpPWpGaD
Acetazolamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0011	0.00259	CcSEcCtD
Acetazolamide—CA3—Metabolism—TPR—thyroid cancer	0.0011	0.00413	CbGpPWpGaD
Acetazolamide—Fatigue—Epirubicin—thyroid cancer	0.0011	0.00258	CcSEcCtD
Acetazolamide—CA4—Metabolism—NDUFA13—thyroid cancer	0.00109	0.00411	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—PRKAR1A—thyroid cancer	0.00108	0.00406	CbGpPWpGaD
Acetazolamide—Paraesthesia—Doxorubicin—thyroid cancer	0.00106	0.00249	CcSEcCtD
Acetazolamide—Feeling abnormal—Epirubicin—thyroid cancer	0.00105	0.00247	CcSEcCtD
Acetazolamide—CA2—Metabolism—NDUFA13—thyroid cancer	0.00105	0.00394	CbGpPWpGaD
Acetazolamide—Somnolence—Doxorubicin—thyroid cancer	0.00105	0.00246	CcSEcCtD
Acetazolamide—CA12—Metabolism—HPGD—thyroid cancer	0.00104	0.0039	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—MINPP1—thyroid cancer	0.00104	0.0039	CbGpPWpGaD
Acetazolamide—Dyspepsia—Doxorubicin—thyroid cancer	0.00104	0.00244	CcSEcCtD
Acetazolamide—CA4—Metabolism—CHST14—thyroid cancer	0.00103	0.00386	CbGpPWpGaD
Acetazolamide—Decreased appetite—Doxorubicin—thyroid cancer	0.00102	0.00241	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00102	0.00239	CcSEcCtD
Acetazolamide—Fatigue—Doxorubicin—thyroid cancer	0.00101	0.00239	CcSEcCtD
Acetazolamide—Urticaria—Epirubicin—thyroid cancer	0.00101	0.00238	CcSEcCtD
Acetazolamide—Body temperature increased—Epirubicin—thyroid cancer	0.00101	0.00237	CcSEcCtD
Acetazolamide—CA1—Metabolism—NDUFA13—thyroid cancer	0.001	0.00378	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—CHST14—thyroid cancer	0.000984	0.0037	CbGpPWpGaD
Acetazolamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00097	0.00228	CcSEcCtD
Acetazolamide—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000967	0.00364	CbGpPWpGaD
Acetazolamide—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000967	0.00364	CbGpPWpGaD
Acetazolamide—CA1—C-MYB transcription factor network—KRAS—thyroid cancer	0.000947	0.00357	CbGpPWpGaD
Acetazolamide—AQP1—Metabolism—SLC5A5—thyroid cancer	0.000947	0.00357	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—CHST14—thyroid cancer	0.000943	0.00355	CbGpPWpGaD
Acetazolamide—Urticaria—Doxorubicin—thyroid cancer	0.000935	0.0022	CcSEcCtD
Acetazolamide—Body temperature increased—Doxorubicin—thyroid cancer	0.00093	0.00219	CcSEcCtD
Acetazolamide—Asthenia—Epirubicin—thyroid cancer	0.000912	0.00215	CcSEcCtD
Acetazolamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000912	0.00344	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—NDUFA13—thyroid cancer	0.000882	0.00332	CbGpPWpGaD
Acetazolamide—Diarrhoea—Epirubicin—thyroid cancer	0.00087	0.00205	CcSEcCtD
Acetazolamide—Asthenia—Doxorubicin—thyroid cancer	0.000844	0.00199	CcSEcCtD
Acetazolamide—Dizziness—Epirubicin—thyroid cancer	0.000841	0.00198	CcSEcCtD
Acetazolamide—CA9—Metabolism—CHST14—thyroid cancer	0.000829	0.00312	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—HPGD—thyroid cancer	0.000827	0.00311	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—SLC5A5—thyroid cancer	0.000821	0.00309	CbGpPWpGaD
Acetazolamide—Vomiting—Epirubicin—thyroid cancer	0.000809	0.0019	CcSEcCtD
Acetazolamide—CA1—C-MYB transcription factor network—HRAS—thyroid cancer	0.000805	0.00303	CbGpPWpGaD
Acetazolamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000805	0.0019	CcSEcCtD
Acetazolamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000805	0.00303	CbGpPWpGaD
Acetazolamide—Headache—Epirubicin—thyroid cancer	0.000797	0.00188	CcSEcCtD
Acetazolamide—AQP1—Metabolism—RXRA—thyroid cancer	0.000795	0.003	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—HPGD—thyroid cancer	0.000793	0.00299	CbGpPWpGaD
Acetazolamide—Dizziness—Doxorubicin—thyroid cancer	0.000778	0.00183	CcSEcCtD
Acetazolamide—CA1—Metabolism—HPGD—thyroid cancer	0.00076	0.00286	CbGpPWpGaD
Acetazolamide—CA9—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000758	0.00286	CbGpPWpGaD
Acetazolamide—Nausea—Epirubicin—thyroid cancer	0.000755	0.00178	CcSEcCtD
Acetazolamide—Vomiting—Doxorubicin—thyroid cancer	0.000748	0.00176	CcSEcCtD
Acetazolamide—CA9—Cellular responses to stress—HIF1A—thyroid cancer	0.000744	0.0028	CbGpPWpGaD
Acetazolamide—Headache—Doxorubicin—thyroid cancer	0.000737	0.00174	CcSEcCtD
Acetazolamide—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000724	0.00273	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—TPR—thyroid cancer	0.000707	0.00266	CbGpPWpGaD
Acetazolamide—Nausea—Doxorubicin—thyroid cancer	0.000699	0.00165	CcSEcCtD
Acetazolamide—CA14—Metabolism—PRKAR1A—thyroid cancer	0.000695	0.00262	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—RXRA—thyroid cancer	0.00069	0.0026	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—TPR—thyroid cancer	0.000689	0.00259	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—TPR—thyroid cancer	0.000689	0.00259	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—PRKAR1A—thyroid cancer	0.000677	0.00255	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—PRKAR1A—thyroid cancer	0.000677	0.00255	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—HPGD—thyroid cancer	0.000668	0.00252	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—TPR—thyroid cancer	0.000643	0.00242	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—TPR—thyroid cancer	0.000643	0.00242	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—PRKAR1A—thyroid cancer	0.000632	0.00238	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—PRKAR1A—thyroid cancer	0.000632	0.00238	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—TPR—thyroid cancer	0.000596	0.00224	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—PRKAR1A—thyroid cancer	0.000586	0.00221	CbGpPWpGaD
Acetazolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000552	0.00208	CbGpPWpGaD
Acetazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000549	0.00207	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—SLC5A5—thyroid cancer	0.000529	0.00199	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—SLC5A5—thyroid cancer	0.000516	0.00194	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—SLC5A5—thyroid cancer	0.000516	0.00194	CbGpPWpGaD
Acetazolamide—AQP1—Metabolism—PPARG—thyroid cancer	0.000502	0.00189	CbGpPWpGaD
Acetazolamide—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000492	0.00185	CbGpPWpGaD
Acetazolamide—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	0.000492	0.00185	CbGpPWpGaD
Acetazolamide—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000484	0.00182	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—SLC5A5—thyroid cancer	0.000481	0.00181	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—SLC5A5—thyroid cancer	0.000481	0.00181	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—TPR—thyroid cancer	0.000475	0.00179	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—PRKAR1A—thyroid cancer	0.000467	0.00176	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—TPR—thyroid cancer	0.000455	0.00171	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—PRKAR1A—thyroid cancer	0.000448	0.00169	CbGpPWpGaD
Acetazolamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000447	0.00168	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—SLC5A5—thyroid cancer	0.000446	0.00168	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—RXRA—thyroid cancer	0.000444	0.00167	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—TPR—thyroid cancer	0.000437	0.00164	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—PPARG—thyroid cancer	0.000435	0.00164	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—RXRA—thyroid cancer	0.000433	0.00163	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—RXRA—thyroid cancer	0.000433	0.00163	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—PRKAR1A—thyroid cancer	0.000429	0.00162	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—RXRA—thyroid cancer	0.000404	0.00152	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—RXRA—thyroid cancer	0.000404	0.00152	CbGpPWpGaD
Acetazolamide—AQP1—Metabolism—PTGS2—thyroid cancer	0.000395	0.00149	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—TPR—thyroid cancer	0.000384	0.00145	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—PRKAR1A—thyroid cancer	0.000378	0.00142	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—RXRA—thyroid cancer	0.000375	0.00141	CbGpPWpGaD
Acetazolamide—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000368	0.00139	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—SLC5A5—thyroid cancer	0.000356	0.00134	CbGpPWpGaD
Acetazolamide—AQP1—Metabolism—PTEN—thyroid cancer	0.000345	0.0013	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—PTGS2—thyroid cancer	0.000343	0.00129	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—SLC5A5—thyroid cancer	0.000341	0.00128	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—SLC5A5—thyroid cancer	0.000327	0.00123	CbGpPWpGaD
Acetazolamide—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000309	0.00116	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—PTEN—thyroid cancer	0.000299	0.00113	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—RXRA—thyroid cancer	0.000299	0.00112	CbGpPWpGaD
Acetazolamide—CA9—Cellular responses to stress—TP53—thyroid cancer	0.000296	0.00112	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—SLC5A5—thyroid cancer	0.000287	0.00108	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—RXRA—thyroid cancer	0.000286	0.00108	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—PPARG—thyroid cancer	0.000281	0.00106	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—RXRA—thyroid cancer	0.000275	0.00103	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—PPARG—thyroid cancer	0.000273	0.00103	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—PPARG—thyroid cancer	0.000273	0.00103	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—PPARG—thyroid cancer	0.000255	0.000961	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—PPARG—thyroid cancer	0.000255	0.000961	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—RXRA—thyroid cancer	0.000241	0.000909	CbGpPWpGaD
Acetazolamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000238	0.000895	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—PPARG—thyroid cancer	0.000237	0.000891	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—PTGS2—thyroid cancer	0.000221	0.000831	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—PTGS2—thyroid cancer	0.000215	0.00081	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—PTGS2—thyroid cancer	0.000215	0.00081	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—PTGS2—thyroid cancer	0.000201	0.000756	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—PTGS2—thyroid cancer	0.000201	0.000756	CbGpPWpGaD
Acetazolamide—AQP1—Metabolism—AKT1—thyroid cancer	0.000199	0.000748	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—PTEN—thyroid cancer	0.000193	0.000725	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—PPARG—thyroid cancer	0.000189	0.00071	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—PTEN—thyroid cancer	0.000188	0.000706	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—PTEN—thyroid cancer	0.000188	0.000706	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—PTGS2—thyroid cancer	0.000186	0.000701	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—PPARG—thyroid cancer	0.000181	0.000681	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—PTEN—thyroid cancer	0.000175	0.00066	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—PTEN—thyroid cancer	0.000175	0.00066	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000175	0.000657	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—PPARG—thyroid cancer	0.000173	0.000653	CbGpPWpGaD
Acetazolamide—CA3—Metabolism—AKT1—thyroid cancer	0.000172	0.000648	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—PTEN—thyroid cancer	0.000162	0.000611	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—PPARG—thyroid cancer	0.000152	0.000574	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000148	0.000559	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—PTGS2—thyroid cancer	0.000148	0.000559	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—PTGS2—thyroid cancer	0.000142	0.000536	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—CHST14—thyroid cancer	0.00014	0.000526	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—PTGS2—thyroid cancer	0.000136	0.000514	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—PTEN—thyroid cancer	0.000129	0.000487	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—PTEN—thyroid cancer	0.000124	0.000467	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—PTGS2—thyroid cancer	0.00012	0.000451	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—PTEN—thyroid cancer	0.000119	0.000448	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000112	0.000424	CbGpPWpGaD
Acetazolamide—CA14—Metabolism—AKT1—thyroid cancer	0.000111	0.000418	CbGpPWpGaD
Acetazolamide—CA5A—Metabolism—AKT1—thyroid cancer	0.000108	0.000407	CbGpPWpGaD
Acetazolamide—CA6—Metabolism—AKT1—thyroid cancer	0.000108	0.000407	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—PTEN—thyroid cancer	0.000105	0.000394	CbGpPWpGaD
Acetazolamide—CA5B—Metabolism—AKT1—thyroid cancer	0.000101	0.00038	CbGpPWpGaD
Acetazolamide—CA7—Metabolism—AKT1—thyroid cancer	0.000101	0.00038	CbGpPWpGaD
Acetazolamide—CA12—Metabolism—AKT1—thyroid cancer	9.35e-05	0.000352	CbGpPWpGaD
Acetazolamide—CA4—Metabolism—AKT1—thyroid cancer	7.46e-05	0.000281	CbGpPWpGaD
Acetazolamide—CA2—Metabolism—AKT1—thyroid cancer	7.15e-05	0.000269	CbGpPWpGaD
Acetazolamide—CA1—Metabolism—AKT1—thyroid cancer	6.85e-05	0.000258	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—TPR—thyroid cancer	6.46e-05	0.000243	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	6.36e-05	0.000239	CbGpPWpGaD
Acetazolamide—CA9—Metabolism—AKT1—thyroid cancer	6.03e-05	0.000227	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.84e-05	0.000182	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—RXRA—thyroid cancer	4.06e-05	0.000153	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—PPARG—thyroid cancer	2.57e-05	9.66e-05	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.02e-05	7.6e-05	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—PTEN—thyroid cancer	1.76e-05	6.63e-05	CbGpPWpGaD
Acetazolamide—CYP3A4—Metabolism—AKT1—thyroid cancer	1.01e-05	3.82e-05	CbGpPWpGaD
